Provided by Tiger Trade Technology Pte. Ltd.

ACADIA Pharmaceuticals

28.93
+0.04000.14%
Post-market: 28.930.00000.00%19:30 EDT
Volume:1.56M
Turnover:45.24M
Market Cap:4.98B
PE:13.18
High:29.75
Open:29.10
Low:28.88
Close:28.89
52wk High:30.96
52wk Low:19.69
Shares:172.31M
Float Shares:128.72M
Volume Ratio:1.39
T/O Rate:1.21%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.20
EPS(LYR):2.30
ROE:35.74%
ROA:3.64%
PB:3.82
PE(LYR):12.58

Loading ...

A Look At ACADIA Pharmaceuticals (ACAD) Valuation As Recent Returns Send Mixed Signals

Simply Wall St.
·
May 02

Acadia R&D chief Elizabeth Thompson to retire, company launches successor search

Reuters
·
May 01

ACADIA Pharmaceuticals Announces Planned Year-End Retirement of Elizabeth H.z. Thompson, Ph.d., Head of Research and Development, Following a Distinguished Career

THOMSON REUTERS
·
May 01

Earning Preview: ACADIA Pharmaceuticals this quarter’s revenue is expected to increase by 17.56%, and institutional views are bullish

Earnings Agent
·
Apr 30

Acadia Pharmaceuticals announces virtual annual shareholder meeting

Reuters
·
Apr 29

ACADIA Pharmaceuticals publishes 2025 annual report

Reuters
·
Apr 29

Analysts Are Bullish on These Healthcare Stocks: Femasys (FEMY), ACADIA Pharmaceuticals (ACAD)

TIPRANKS
·
Apr 28

Acadia presents Phase 4 LOTUS real-world DAYBUE data in Rett syndrome at AAN 2026

Reuters
·
Apr 17

Bank of America Securities Remains a Buy on ACADIA Pharmaceuticals (ACAD)

TIPRANKS
·
Apr 16

Acadia Pharmaceuticals to report first-quarter results after US market close

Reuters
·
Apr 16

Did DAYBUE STIX’s Flexible Rett Formulation Just Shift ACADIA Pharmaceuticals' (ACAD) Investment Narrative?

Simply Wall St.
·
Apr 16

A Look At Acadia Pharmaceuticals (ACAD) Valuation After DAYBUE STIX US Launch

Simply Wall St.
·
Apr 11

RBC Capital Remains a Buy on ACADIA Pharmaceuticals (ACAD)

TIPRANKS
·
Apr 09

Acadia Pharmaceuticals announces Daybue Stix available in U.S.

TIPRANKS
·
Apr 07

ACADIA Pharmaceuticals Announces Daybue® Stix (Trofinetide) Is NOW Broadly Available in the United States for the Treatment of Rett Syndrome

THOMSON REUTERS
·
Apr 07

RBC Capital Adjusts ACADIA Pharmaceuticals PT to $29 From $30, Maintains Outperform Rating

MT Newswires Live
·
Apr 07

ACADIA Pharmaceuticals Shares Rise After BofA Upgrade

MT Newswires Live
·
Mar 26

BofA Securities Upgrades ACADIA Pharmaceuticals to Buy From Neutral, Price Target is $29

MT Newswires Live
·
Mar 25

ACADIA Pharmaceuticals Raised to Buy From Neutral by B of A Securities

Dow Jones
·
Mar 25

U.S. RESEARCH ROUNDUP-Amazon, Diamondback Energy, Matador Resources

Reuters
·
Mar 25